TNFRSF1A and neoplasm: These include the tumor necrosis factor receptor 1 (TNFR1), tumornecrosis factor receptor 6 (CD95, FasR, APO-1), death receptor 4 (DR4), deathreceptor 5 (DR5), etc. Receptors DR4 and DR5 are the most promising candidatesfor targeted therapy of tumor diseases, because their expression levels aresignificantly higher in cancer cells than in normal ones[4, 5].Therefore, unlike chemotherapeutic agents, these receptors may potentiallymediate selective killing of tumor cells.